First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Market Cap ($613.49 Million)
Market Cap & Net Worth: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued market cap. First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (NASDAQ:TRAXV) has a market capitalization of $613.49 Million ($613.49 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10831 globally and #2873 in its home market, demonstrating a -3.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's stock price $17.66 by its total outstanding shares 34748841 (34.75 Million).
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Market Cap History (2026–2026)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued market cap history from 2026 to 2026. Data shows growth from $613.49 Million to $613.49 Million (0.00% CAGR). Check TRAXV live share price for real-time trading data and today's change.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see First Tracks Biotherapeutics, Inc. Ordin operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TRAXV by Market Capitalization
Companies near First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued in the global market cap rankings as of October 31, 2026. See TRAXV equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2026–2026)
Market capitalization of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2026 to today. Between 2026 and today, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's market cap moved from $613.49 Million to $ 613.49 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $613.49 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $613.49 Million USD |
| MoneyControl | $613.49 Million USD |
| MarketWatch | $613.49 Million USD |
| marketcap.company | $613.49 Million USD |
| Reuters | $613.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more